Clover Health Investments Statistics
Total Valuation
CLOV has a market cap or net worth of $961.55 million. The enterprise value is $883.25 million.
Important Dates
The next estimated earnings date is Tuesday, May 5, 2026, after market close.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CLOV has 485.63 million shares outstanding. The number of shares has increased by 4.48% in one year.
| Current Share Class | 428.95M |
| Shares Outstanding | 485.63M |
| Shares Change (YoY) | +4.48% |
| Shares Change (QoQ) | +0.88% |
| Owned by Insiders (%) | 21.42% |
| Owned by Institutions (%) | 25.66% |
| Float | 408.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 22.23 |
| PS Ratio | 0.50 |
| Forward PS | 0.35 |
| PB Ratio | 3.33 |
| P/TBV Ratio | 3.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.47
| Current Ratio | 1.47 |
| Quick Ratio | 1.34 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -26.33% and return on invested capital (ROIC) is -16.45%.
| Return on Equity (ROE) | -26.33% |
| Return on Assets (ROA) | -9.53% |
| Return on Invested Capital (ROIC) | -16.45% |
| Return on Capital Employed (ROCE) | -25.75% |
| Weighted Average Cost of Capital (WACC) | 16.54% |
| Revenue Per Employee | $2.66M |
| Profits Per Employee | -$118,162 |
| Employee Count | 724 |
| Asset Turnover | 3.43 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.15% in the last 52 weeks. The beta is 2.24, so CLOV's price volatility has been higher than the market average.
| Beta (5Y) | 2.24 |
| 52-Week Price Change | -45.15% |
| 50-Day Moving Average | 2.25 |
| 200-Day Moving Average | 2.68 |
| Relative Strength Index (RSI) | 41.29 |
| Average Volume (20 Days) | 5,251,630 |
Short Selling Information
The latest short interest is 38.47 million, so 7.92% of the outstanding shares have been sold short.
| Short Interest | 38.47M |
| Short Previous Month | 41.09M |
| Short % of Shares Out | 7.92% |
| Short % of Float | 9.41% |
| Short Ratio (days to cover) | 6.17 |
Income Statement
In the last 12 months, CLOV had revenue of $1.92 billion and -$85.55 million in losses. Loss per share was -$0.17.
| Revenue | 1.92B |
| Gross Profit | 355.10M |
| Operating Income | -85.53M |
| Pretax Income | -85.55M |
| Net Income | -85.55M |
| EBITDA | -83.84M |
| EBIT | -85.53M |
| Loss Per Share | -$0.17 |
Full Income StatementBalance Sheet
The company has $120.26 million in cash and n/a in debt, with a net cash position of $78.30 million or $0.16 per share.
| Cash & Cash Equivalents | 120.26M |
| Total Debt | n/a |
| Net Cash | 78.30M |
| Net Cash Per Share | $0.16 |
| Equity (Book Value) | 308.70M |
| Book Value Per Share | 0.59 |
| Working Capital | 99.03M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$66.93 million and capital expenditures -$2.04 million, giving a free cash flow of -$68.98 million.
| Operating Cash Flow | -66.93M |
| Capital Expenditures | -2.04M |
| Free Cash Flow | -68.98M |
| FCF Per Share | -$0.14 |
Full Cash Flow StatementMargins
Gross margin is 18.46%, with operating and profit margins of -4.45% and -4.45%.
| Gross Margin | 18.46% |
| Operating Margin | -4.45% |
| Pretax Margin | -4.45% |
| Profit Margin | -4.45% |
| EBITDA Margin | -4.36% |
| EBIT Margin | -4.45% |
| FCF Margin | n/a |
Dividends & Yields
CLOV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.48% |
| Shareholder Yield | -4.48% |
| Earnings Yield | -8.90% |
| FCF Yield | -7.17% |
Analyst Forecast
The average price target for CLOV is $3.07, which is 55.05% higher than the current price. The consensus rating is "Buy".
| Price Target | $3.07 |
| Price Target Difference | 55.05% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 18.24% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
